Terry Hyslop

Positions:

Professor of Biostatistics & Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 2001

Temple University

Grants:

Combined breast MRI/biomarker strategies to identify aggressive biology

Administered By
Integrative Genomics
Role
Principal Investigator
Start Date
End Date

Combined breast MRI/biomarker strategies to identify aggressive biology

Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Biostatistician
Start Date
End Date

Tension-Stat3-miR-mediated metastasis

Administered By
Medicine, Medical Oncology
Awarded By
University of California, San Francisco
Role
Biostatistician
Start Date
End Date

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Smartphone Enabled Point-of-Care Detection of Serum Markers of Liver Cancer

Administered By
Biomedical Engineering
Awarded By
National Institutes of Health
Role
Co Investigator
Start Date
End Date

Publications:

Racial differences in Helicobacter pylori antibody prevalence by year of birth and demographic factors in a consortium of US adults

Authors
Varga, MG; Butt, J; Blot, WJ; Le Marchand, L; Haiman, C; Chen, Y; Wassertheil-Smoller, S; Ho, GYF; Tinker, LE; Peek, RM; Potter, JD; Cover, TL; Hendrix, L; Hyslop, T; Zeleniuch-Jacquotte, A; Berndt, S; Hildesheim, A; Waterboer, T; Pawlita, M; EPPlein, M
URI
https://scholars.duke.edu/individual/pub1415374
Source
wos
Published In
Helicobacter
Volume
24
Published Date

Breast Cancer in Tanzanian Patients: An Assessment of Tumor Type, Grade, Biomarker status, and Tumor Infiltrating Lymphocytes

Authors
Mremi, A; Broadwater, G; Hyslop, T; Hall, A
MLA Citation
Mremi, Alex, et al. “Breast Cancer in Tanzanian Patients: An Assessment of Tumor Type, Grade, Biomarker status, and Tumor Infiltrating Lymphocytes.” Modern Pathology, vol. 32, NATURE PUBLISHING GROUP, 2019.
URI
https://scholars.duke.edu/individual/pub1404160
Source
wos
Published In
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
Volume
32
Published Date

GUCY2C Analysis Accurately Stratifies Risk for Recurrence in Early Stage CRC

Authors
Weinberg, D; Hyslop, T; Barkun, AN; Schulz, S; Waldman, SA
MLA Citation
Weinberg, David, et al. “GUCY2C Analysis Accurately Stratifies Risk for Recurrence in Early Stage CRC.” Gastroenterology, vol. 138, no. 5, W B SAUNDERS CO-ELSEVIER INC, 2010, pp. S18–19.
URI
https://scholars.duke.edu/individual/pub1404162
Source
wos
Published In
Gastroenterology
Volume
138
Published Date
Start Page
S18
End Page
S19

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.

Notwithstanding the positive clinical impact of endocrine therapies in estrogen receptor-alpha (ERα)-positive breast cancer, de novo and acquired resistance limits the therapeutic lifespan of existing drugs. Taking the position that resistance is nearly inevitable, we undertook a study to identify and exploit targetable vulnerabilities that were manifest in endocrine therapy-resistant disease. Using cellular and mouse models of endocrine therapy-sensitive and endocrine therapy-resistant breast cancer, together with contemporary discovery platforms, we identified a targetable pathway that is composed of the transcription factors FOXA1 and GRHL2, a coregulated target gene, the membrane receptor LYPD3, and the LYPD3 ligand, AGR2. Inhibition of the activity of this pathway using blocking antibodies directed against LYPD3 or AGR2 inhibits the growth of endocrine therapy-resistant tumors in mice, providing the rationale for near-term clinical development of humanized antibodies directed against these proteins.
Authors
Cocce, KJ; Jasper, JS; Desautels, TK; Everett, L; Wardell, S; Westerling, T; Baldi, R; Wright, TM; Tavares, K; Yllanes, A; Bae, Y; Blitzer, JT; Logsdon, C; Rakiec, DP; Ruddy, DA; Jiang, T; Broadwater, G; Hyslop, T; Hall, A; Laine, M; Phung, L; Greene, GL; Martin, L-A; Pancholi, S; Dowsett, M; Detre, S; Marks, JR; Crawford, GE; Brown, M; Norris, JD; Chang, C-Y; McDonnell, DP
MLA Citation
Cocce, Kimberly J., et al. “The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer..” Cell Rep, vol. 29, no. 4, Oct. 2019, pp. 889-903.e10. Pubmed, doi:10.1016/j.celrep.2019.09.032.
URI
https://scholars.duke.edu/individual/pub1416479
PMID
31644911
Source
pubmed
Published In
Cell Reports
Volume
29
Published Date
Start Page
889
End Page
903.e10
DOI
10.1016/j.celrep.2019.09.032

Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.

BACKGROUND: Randomised trials comparing the efficacy of standard endocrine therapy (ET) versus experimental ET + bevacizumab (Bev) in 1st line hormone receptor-positive patients with metastatic breast cancer have thus far shown conflicting results. PATIENTS AND METHODS: We pooled data from two similar phase III randomised trials of ET ± Bev (LEA and Cancer and Leukemia Group B 40503) to increase precision in estimating treatment effect. Primary end-point was progression-free survival (PFS). Secondary end-points were overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR) and safety. Exploratory analyses were performed within subgroups defined by patients with recurrent disease, de novo disease, prior endocrine sensitivity or resistance and reported grades III-IV hypertension and proteinuria. RESULTS: The pooled sample consisted of 749 patients randomised to ET or ET + Bev. Median PFS was 14.3 months for ET versus 19 months for ET + Bev (unadjusted hazard ratio [HR] 0.77; 95% confidence interval [CI] 0.66-0.91; p < 0.01). ORR and CBR with ET and ET + Bev were 40 versus 61% (p < 0.01) and 64 versus 77% (p < 0.01), respectively. There was no difference in OS (HR 0.96; 95% CI 0.77-1.18; p = 0.68). PFS was superior for ET + Bev for endocrine-sensitive patients (HR 0.68; 95% CI 0.53-0.89; p = 0.004). Grade III-IV hypertension (2.2 versus 20.1%), proteinuria (0 versus 9.3%), cardiovascular (0.5 versus 4.2%) and liver events (0 versus 2.9%) were significantly higher for ET + Bev (all p < 0.01). Hypertension and proteinuria were not predictors of efficacy (interaction test p = 0.33). CONCLUSION: The addition of Bev to ET increased PFS overall and in endocrine-sensitive patients but not OS at the expense of significant additional toxicity. TRIALS REGISTRATION: ClinicalTrial.Gov NCT00545077 and NCT00601900.
Authors
Martín, M; Loibl, S; Hyslop, T; De la Haba-Rodríguez, J; Aktas, B; Cirrincione, CT; Mehta, K; Barry, WT; Morales, S; Carey, LA; Garcia-Saenz, JA; Partridge, A; Martinez-Jañez, N; Hahn, O; Winer, E; Guerrero-Zotano, A; Hudis, C; Casas, M; Rodriguez-Martin, C; Furlanetto, J; Carrasco, E; Dickler, MN; GEICAM Spanish Breast Cancer Group,; GBG (German Breast Group),; Alliance for Clinical Trials in Oncology (Alliance),
URI
https://scholars.duke.edu/individual/pub1395967
PMID
31276981
Source
pubmed
Published In
Eur J Cancer
Volume
117
Published Date
Start Page
91
End Page
98
DOI
10.1016/j.ejca.2019.06.002

Research Areas:

Breast Neoplasms
Cohort Studies
Colorectal Neoplasms
Gastrointestinal Hormones
Gastrointestinal Tract
Italy
Lung Neoplasms
Models, Statistical
Neoplasm Invasiveness
Prognosis
Socioeconomic Factors
Survival Analysis
Thyroid Neoplasms
Thyroidectomy
Urogenital System